Halozyme Therapeutics/HALO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Halozyme Therapeutics
Ticker
HALO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
373
Website
halozyme.com
HALO Metrics
BasicAdvanced
$6.5B
Market cap
21.21
P/E ratio
$2.42
EPS
1.28
Beta
-
Dividend rate
Price and volume
Market cap
$6.5B
Beta
1.28
Financial strength
Current ratio
6.636
Quick ratio
5.009
Long term debt to equity
861.649
Total debt to equity
861.965
Interest coverage (TTM)
20.39%
Management effectiveness
Return on assets (TTM)
13.48%
Return on equity (TTM)
261.68%
Valuation
Price to earnings (TTM)
21.21
Price to revenue (TTM)
7.72
Price to book
36.77
Price to tangible book (TTM)
-9.42
Price to free cash flow (TTM)
15.73
Growth
Revenue change (TTM)
22.41%
Earnings per share change (TTM)
86.04%
3-year revenue growth
37.60%
3-year earnings per share growth
29.04%
What the Analysts think about HALO
Analyst Ratings
Majority rating from 11 analysts.
HALO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$196M
-14.87%
Net income
$77M
-9.96%
Profit margin
39.22%
5.77%
HALO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.74
$0.75
$0.82
$0.79
-
Expected
$0.63
$0.71
$0.83
$0.70
$0.75
Surprise
17.62%
6.04%
-0.61%
13.67%
-
HALO News
AllArticlesVideos
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Investors Business Daily·19 hours ago
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
PRNewsWire·1 week ago
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $6.5B as of July 04, 2024.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 21.21 as of July 04, 2024.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Halozyme Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.